ARTH Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 22:32):

Stats
Dzisiejszy wolumen	2 432.00
Średni wolumen	3 344.00
Kapitalizacja rynkowa	5.60M
EPS	$0 ( 2024-01-05 )
Następna data zysków	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.840
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-31	Abrams Michael S	Buy	20 584	Warrants (right to buy)
2023-08-31	Abrams Michael S	Buy	10 292	Common Stock
2023-08-31	Norchi Terrence W	Buy	13 724	Warrants (right to buy)
2023-08-31	Norchi Terrence W	Buy	6 862	Common Stock
2023-08-31	Hicks Laurence	Buy	20 584	Warrants (right to buy)

INSIDER POWER
100.00
Last 89 transactions
Buy: 27 633 666 \| Sell: 2 335 000

Arch Therapeutics, Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Arch Therapeutics, Inc. Finanse

Annual	2023
Przychody:	$75 724.00
Zysk brutto:	$-2 439.00 (-3.22 %)
EPS:	$-2.27

FY	2023
Przychody:	$75 724.00
Zysk brutto:	$-2 439.00 (-3.22 %)
EPS:	$-2.27

FY	2022
Przychody:	$15 652.00
Zysk brutto:	$-35 837.00 (-228.96 %)
EPS:	$-3.56

FY	2021
Przychody:	$11 565.00
Zysk brutto:	$-14 717.00 (-127.25 %)
EPS:	$-0.0300

Financial Reports:

No articles found.

Arch Therapeutics, Inc.

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.